Treadmill gait training for people with MS; does it improve gait or reduce fatigue?
| ISRCTN | ISRCTN78460965 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN78460965 |
| Protocol serial number | N0176120461 |
| Sponsor | Department of Health (UK) |
| Funder | Oxford Radcliffe Hospitals NHS Trust (UK) |
- Submission date
- 12/09/2003
- Registration date
- 12/09/2003
- Last edited
- 22/09/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Helen Dawes
Scientific
Scientific
School of Biological & Molecular Sciences
Oxford Brookes University
Gypsy Lane Campus
Headington
Oxford
OX3 OB
United Kingdom
| Phone | +44 (0)1865 483293 |
|---|---|
| hdawes@brookes.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Crossover randomised controlled design study |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | In individuals with multiple sclerosis (MS), who have impaired walking but are able to walk on a treadmill: 1. Can treadmill training improve the speed and/or distance an individual can walk? 2. Can treadmill training improve an individual's general state of well-being? 3. Is treadmill training harmful following multiple sclerosis? |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Nervous System Diseases: Multiple sclerosis (MS) |
| Intervention | One group of patients receives treadmill training for 4 weeks, then no training. A second group of patients receives no training for 4 weeks, then 4 weeks training. Each group is assessed at week 5 and week 10. |
| Intervention type | Other |
| Primary outcome measure(s) |
The primary outcome measures will be functional mobility as measured by the Rivermead Mobility Index, 10 m and 2 min walk tests and fatigue as measured by the Fatigue Severity Scale at each time point. |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 30/11/2003 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 24 |
| Key inclusion criteria | 12-24 individuals with multiple sclerosis. |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 10/03/2003 |
| Date of final enrolment | 30/11/2003 |
Locations
Countries of recruitment
- United Kingdom
Study participating centre
School of Biological & Molecular Sciences
Oxford
OX3 OB
United Kingdom
OX3 OB
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/01/2007 | Yes | No |
